ATNF's Business Model
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://180lifesciences.com |
| CEO (Chief Executive Officer) | Lloyd Blair Jordan |
| Number of Employees | |
| IPO date | June 27, 2017 |
ATNF Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | Building 4 |
| City | Palo Alto |
| State | CA |
| Phone | 650 507 0669 |
| Zip Code | 94306 |
| Other Identifiers | |
| CIK | 0001690080 |
| ISIN | US68236V3024 |
| CUSIP | 68236V104 |
| Open | 0.9 |
| Previous Close | 0.9 |
| Volume | 110.3 Thou. |
| Average Volume | 116.2 Thou. |
| Day’s Range | 0.8779 – 0.91 |
| 52 Week Range | 0.658-17.75 |
| MA (50) | 1.00542 |
| MA (200) | 1.61971 |
| Market Cap | 5.37 Mil. |
| Shares Out. | 6.04 Mil. |
| Earnings Date | Aug 11, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
